United States Policy Implications of Generic Substitution of Branded Human Immunodeficiency Virus Medications
Hogue, S., Brogan, A., & Goodwin, B. (2013). United States Policy Implications of Generic Substitution of Branded Human Immunodeficiency Virus Medications. Value in Health, 16(7), A364-A365.
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.
Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Spatiotemporal analysis exploring the effect of law enforcement drug market disruptions on overdose, Indianapolis, Indiana, 2020-2021